Blue Zone Wealth Advisors LLC Invests $243,000 in Eli Lilly and Company (NYSE:LLY)

Blue Zone Wealth Advisors LLC bought a new stake in Eli Lilly and Company (NYSE:LLY) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 274 shares of the company’s stock, valued at approximately $243,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LLY. Regal Investment Advisors LLC grew its stake in Eli Lilly and Company by 41.3% during the 4th quarter. Regal Investment Advisors LLC now owns 4,808 shares of the company’s stock worth $2,803,000 after buying an additional 1,405 shares during the last quarter. VitalStone Financial LLC grew its position in shares of Eli Lilly and Company by 35.5% during the fourth quarter. VitalStone Financial LLC now owns 1,249 shares of the company’s stock worth $728,000 after acquiring an additional 327 shares during the last quarter. Advanced Portfolio Management LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $1,736,000. Visionary Wealth Advisors raised its position in Eli Lilly and Company by 2.7% in the 4th quarter. Visionary Wealth Advisors now owns 1,872 shares of the company’s stock valued at $1,091,000 after purchasing an additional 49 shares during the last quarter. Finally, Bridgewater Associates LP boosted its stake in Eli Lilly and Company by 412.5% during the 4th quarter. Bridgewater Associates LP now owns 317,586 shares of the company’s stock worth $185,127,000 after purchasing an additional 255,619 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have commented on LLY. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Guggenheim upped their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Truist Financial reaffirmed a “buy” rating and set a $1,000.00 price objective (up from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Citigroup started coverage on Eli Lilly and Company in a report on Friday, September 13th. They issued a “buy” rating and a $1,060.00 target price on the stock. Finally, Berenberg Bank increased their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $977.35.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the sale, the insider now directly owns 96,943,810 shares of the company’s stock, valued at approximately $91,109,731,514.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 1.3 %

Shares of NYSE LLY opened at $898.40 on Tuesday. The firm has a market cap of $853.84 billion, a P/E ratio of 132.31, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. Eli Lilly and Company has a 1 year low of $547.61 and a 1 year high of $972.53. The firm’s 50 day moving average price is $900.13 and its 200 day moving average price is $848.40.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The firm had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.